Trial Search Results

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

Although prior dose-finding studies have investigated the optimal bolus dose of oxytocin to initiate adequate uterine tone, it is unclear what oxytocin infusion regimen is required to maintain adequate uterine tone after delivery. The study investigators aim to compare two different infusion rates of oxytocin to assess the optimal infusion regimen for reducing blood loss in women undergoing elective Cesarean delivery.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Oxytocin Infusion


Phase 3


Inclusion Criteria:

   - Healthy pregnant patients with uncomplicated pregnancies:

   - ASA (American Association of Anesthesiologists) class 1 or 2 patients.

   - Singleton pregnancies.

Exclusion Criteria:

   - ASA class 3 or 4 patients.

   - Known drug allergy to intravenous oxytocin.

   - Significant medical or obstetric disease.

   - Known uterine abnormality.

   - Known placental abnormality.

Ages Eligible for Study

18 Years - 40 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Alexander J Butwick, F.R.C.A